Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | CCR3 | P51677 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902860 | 0.98 | ACHE (0.65) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL10513195 | 0.89 | ACHE (0.58) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL8315434 | 0.83 | ACHE (0.71) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL4257757 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL7363662 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL2010139 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL1147100 | 0.81 | CCR3 (0.71) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL1415730 | 0.80 | SIGMAR1 (1.00) | ACHESIGMAR1CCR3DRD4MC4R | |
| SCHEMBL8188324 | 0.80 | SIGMAR1 (1.00) | ACHESIGMAR1CCR3DRD4MC4R | |
| SCHEMBL2489199 | 0.80 | SIGMAR1 (1.00) | ACHESIGMAR1CCR3DRD4MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111302880-B | Application of iron catalyst in reduction coupling reaction and preparation method of aromatic ring and heterocyclic derivative | 川北医学院 | 2022-09-13 | — | — | CN | claimed |
| CN-111302880-A | Application of iron catalyst in reduction coupling reaction and preparation method of aromatic ring and heterocyclic derivative | 川北医学院 | 2020-06-19 | — | — | CN | claimed |
| CN-111302880-B | Application of iron catalyst in reduction coupling reaction and preparation method of aromatic ring and heterocyclic derivative | 川北医学院 | 2022-09-13 | — | — | CN | disclosed |
| CN-111302880-A | Application of iron catalyst in reduction coupling reaction and preparation method of aromatic ring and heterocyclic derivative | 川北医学院 | 2020-06-19 | — | — | CN | disclosed |
| WO-2014116684-A1 | NON-PEPTIDIC NEUROPEPTIDE Y RECEPTOR MODULATORS | ROBERTS EDWARD (US) | 2014-07-31 | — | — | WO | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| CN-1960977-A | Quinazoline derivative | BANYU PHARMA CO LTD (JP) | 2007-05-09 | — | — | CN | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | ACHE 2005/4885SIGMAR1 202/4885CCR3 1734/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | ACHE 657/4885SIGMAR1 500/4885CCR3 1088/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | ACHE 2901/4885SIGMAR1 1024/4885CCR3 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.